ACCELERON PHARMA INC Insider Trading for May 2014
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC for May 2014.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Option Exercise | M | 0.48 | 6,000 | 2,880 | 53,765 | |
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.97 | 6,000 | 185,820 | 15,858 | 21.9 K to 15.9 K (-27.45 %) |
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Buy | M | 0.48 | 6,000 | 2,880 | 21,858 | 15.9 K to 21.9 K (+37.84 %) |
| May 30 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 30.99 | 1,500 | 46,485 | 34,500 | 36 K to 34.5 K (-4.17 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 5,000 | 29,400 | 20,000 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.27 | 200 | 6,454 | 41,890 | 42.1 K to 41.9 K (-0.48 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 31.51 | 1,800 | 56,718 | 42,090 | 43.9 K to 42.1 K (-4.10 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 32.13 | 500 | 16,065 | 43,890 | 44.4 K to 43.9 K (-1.13 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 31.23 | 6,500 | 202,995 | 44,390 | 50.9 K to 44.4 K (-12.77 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 5,000 | 29,400 | 50,890 | 45.9 K to 50.9 K (+10.90 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 31.68 | 500 | 15,840 | 36,000 | 36.5 K to 36 K (-1.37 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 32.23 | 100 | 3,223 | 15,858 | 16 K to 15.9 K (-0.63 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | SVP & Chief Medical ... | Sell | S | 31.47 | 1,900 | 59,793 | 15,958 | 17.9 K to 16 K (-10.64 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 5.08 | 7,500 | 38,100 | 48,750 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Option Exercise | M | 0.40 | 2,500 | 1,000 | 11,875 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.19 | 391 | 12,586 | 27,656 | 28 K to 27.7 K (-1.39 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 31.48 | 7,109 | 223,791 | 28,047 | 35.2 K to 28 K (-20.22 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 5.08 | 7,500 | 38,100 | 35,156 | 27.7 K to 35.2 K (+27.12 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 32.35 | 100 | 3,235 | 27,656 | 27.8 K to 27.7 K (-0.36 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Sell | S | 31.49 | 2,400 | 75,576 | 27,756 | 30.2 K to 27.8 K (-7.96 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | SVP & Chief Busines ... | Buy | M | 0.40 | 2,500 | 1,000 | 30,156 | 27.7 K to 30.2 K (+9.04 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.20 | 287 | 9,241 | 206,500 | 206.8 K to 206.5 K (-0.14 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.49 | 9,713 | 305,862 | 206,787 | 216.5 K to 206.8 K (-4.49 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.23 | 100 | 3,223 | 216,500 | 216.6 K to 216.5 K (-0.05 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.51 | 4,900 | 154,399 | 216,600 | 221.5 K to 216.6 K (-2.21 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 205,751 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 3,000 | 11,640 | 212,751 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.17 | 286 | 9,201 | 0 | 286 to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.49 | 6,714 | 211,424 | 286 | 7 K to 286 (-95.91 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.27 | 100 | 3,227 | 0 | 100 to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.48 | 2,900 | 91,292 | 100 | 3 K to 100 (-96.67 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 3,000 | 11,640 | 3,000 | 0 to 3 K |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 3.88 | 7,000 | 27,160 | 55,500 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Option Exercise | M | 0.92 | 2,000 | 1,840 | 23,500 | |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 32.20 | 900 | 28,980 | 0 | 900 to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 31.29 | 6,100 | 190,869 | 900 | 7 K to 900 (-87.14 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 3.88 | 7,000 | 27,160 | 7,000 | 0 to 7 K |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Sell | S | 31.49 | 2,000 | 62,980 | 0 | 2 K to 0 (-100.00 %) |
| May 21 2014 | XLRN | ACCELERON PHARMA I ... | Quisel John D | VP General Counsel ... | Buy | M | 0.92 | 2,000 | 1,840 | 2,000 | 0 to 2 K |
| May 07 2014 | XLRN | ACCELERON PHARMA I ... | Polaris Venture Management Co ... | 10% Owner | Sell | S | 42.86 | 313,491 | 13,436,224 | 2,819,743 | 3.1 M to 2.8 M (-10.01 %) |
| May 07 2014 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | S | 42.86 | 313,491 | 13,436,224 | 2,819,743 | 3.1 M to 2.8 M (-10.01 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 42.86 | 12,263 | 525,592 | 60,496 | 72.8 K to 60.5 K (-16.85 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | KANIA EDWIN M JR | Director | Sell | S | 42.86 | 202,879 | 8,695,394 | 1,000,841 | 1.2 M to 1 M (-16.85 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | George Jean | Director | Sell | S | 42.86 | 215,644 | 9,242,502 | 1,939,031 | 2.2 M to 1.9 M (-10.01 %) |
| May 06 2014 | XLRN | ACCELERON PHARMA I ... | CELGENE CORP /DE/ | 10% Owner | Buy | P | 42.86 | 1,100,000 | 47,146,000 | 4,572,887 | 3.5 M to 4.6 M (+31.67 %) |